SPOTLIGHT: Meridian buys recombinant proteins


Meridian Bioscience has agreed to buy a line of infectious disease recombinant proteins from Vybion for an undisclosed sum of money. The pact covers future royalties on product sales. Release | Report

Suggested Articles

MyoKardia wasn’t looking for a buyout when it started discussing potential partnerships with Bristol Myers Squibb last year.

The patient was hospitalized with febrile neutropenia in the weeks after receiving the drug and died 52 days post-treatment with the CAR-T therapy.

The trial has been paused since early September while FDA reviews the safety of the vaccine in light of a reported case of an inflammatory disorder.